Background/Aims: Monocyte activation and subsequent cytokine generation is presumed to be involved in haemodialysis (HD)-related morbidity. The present study was designed to investigate HD-induced changes in monocytes, with respect to their phenotypic profile and cytokine release, both in peripheral blood (PB) and dialyser eluates (DE). In addition, the effect of the type of dialyser on monocyte activation was assessed. Methods: Dialyser elution was performed in 8 patients after 3 h of HD, using cuprammonium (CU) and polysulfon (PS) dialysers in a randomised cross-over design. PB samples and DE were analysed for both the expression of a variety of monocyte cell surface markers (CD62L, CD11b, CD25, HLA-DR, CD64 and CD14) by flow cytometry and IL-1β levels. Monocytes were identified by dual labelling with antibodies against CD14. Results: In PB, the expression of CD11b increased during HD with both devices, but was more pronounced with CU (CU versus PS: p < 0.05). CD62L decreased during HD, but only significantly for PS (p < 0.02). HLA-DR was downregulated during HD with CU (p = 0.056). The expression of CD64 was higher during HD with CU (p = 0.02). Finally, CD14 increased during HD with both dialysers (p < 0.03). DE yielded a mean cell count of 51 × 106 cells. The proportion of monocytes in DE was 3% for CU and 4% for PS. In eluted monocytes, a significant upregulation of CD11b, CD25, and HLA-DR was observed. CD62L was downregulated when compared to PB at t180 (p < 0.001). In DE, no correlation was found between the type of dialyser and the phenotypic changes. In 10 of 16 DE supernatants, 6 CU and 4 PS, IL-1β release could be demonstrated, CU yielding significantly more of this cytokine than PS (p = 0.03). Conclusions: According to both their phenotypic profile and cytokine release, monocytes sticking to the dialyser membrane after HD are considerably more activated than circulating monocytes. Activation of eluted monocytes appeared independent of the type of dialyser, suggesting an effect of mechanical stress rather than bioincompatibility. In contrast, phenotypic activation of peripheral blood monocytes and cytokine release in the DE supernatant were mainly dialyser-dependent.

Keywords:
Bioincompatibility, Cell surface markers, Eluates, Haemodialysis, Interleukin-1β, Monocytes, Phenotype
1.
Vanholder R, van Loo A, Dhondt AM, de Smet R, Rignoir S: Influence of uraemia and haemodialysis on host defence and infection. Nephrol Dial Transplant 1996;11:593–598.
2.
Chatenoud L, Herbelin A, Beaurain G, Descamps-Latscha B: Immune deficiency of the uremic patients. Adv Nephrol 1990;19:259–274.
3.
Descamps-Latscha B, Herbelin A, Nguyen AT, Roux-Lombard P, Zingraff J, Moynot A, Verger C, Dahmane D, de Groote D, Jungers P, Dayer JM: Balance between IL-1β, TNF-α, and their specific inhibitors in chronic renal failure and maintenance dialysis. J Immunol 1995;154:882–892.
4.
Schiller B, Ziegler-Heitbrock HWL, Meyer N, Schmidt B, Blumenstein M: Monocyte phenotype and interleukin-1 production in patients undergoing haemodialysis. Nephron 1991;59:573–579.
5.
Von Appen K, Goolsby C, Mehl P, Goewert R, Ivanovich P: Leukocyte adhesion molecules as biocompatibility markers for hemodialysis membranes. ASAIO J 1994;40:M609–M615.
6.
Ruiz P, Gomez F, Schreibner AD: Impaired function of macrophage Fcγ receptors in end-stage renal disease. N Engl J Med 1990;322:717–722.
7.
Roccatello D, Mazzucco G, Coppo R, Piccoli G, Rollino C, Scalzo B, Guerra MG, Cavalli G, Giachino O, Amore A, Malavasi F, Sena LM: Functional changes of monocytes due to dialysis membranes. Kidney Int 1989;35:622–631.
8.
Henderson LW, Koch KM, Dinarello CA, Shaldon S: Hemodialysis hypotension: The interleukin hypothesis. Blood Purif 1983;1:3–8.
9.
Pertosa G, Tarantino EA, Gesualdo L, Montinaro V, Schena FP: C5b-9 generation and cytokine production in hemodialyzed patients. Kidney Int 1993;43(suppl 41):S221–S225.
10.
Haeffner-Cavaillon N, Jahns G, Poignet JL, Kazatchkine MD: Induction of interleukin-1 during hemodialysis. Kidney Int 1993;43(suppl 39):S139–S143.
11.
Panichi V, Casarosa L, Gattai V, Bianchi AM, Andreini B, Migliori M, de Pietro S, Giovannini L, Palla R: Protein layer on hemodialysis membranes: A new immunohistochemistry technique. Int J Artif Organs 1995;18:305–308.
12.
Luger A, Kovarik J, Stummvoll HK, Urbanska A, Luger TA: Blood-membrane interaction in hemodialysis leads to increased cytokine production. Kidney Int 1987;32:84–88.
13.
David S, Tetta C, Camussi G, Canino F, Almici C, Rizzoli V, Cambi V: Adherence of human monocytes to haemodialysis membranes. Nephrol Dial Transplant 1993;8:1223–1227.
14.
Leonard AF, van Vooren C, Hauglustaine D, Haumont S: Shear-induced formation of aggregates during hemodialysis; in Baldamus CA, Schoeppe W, Koch KM (eds): Biocompatibility in Hemodialysis. Contrib Nephrol. Basel, Karger, 1983, vol 36, pp 34–45.
15.
Bingel M, Lonneman G, Koch KM, Dinarello CA, Shaldon S: Enhancement of in-vitro human interleukin-1 production by sodium acetate. Lancet 1987;i:14–16.
16.
Schindler R, Krautzig S, Lufft V, Lonnemann G, Mahiout A, Marra MN, Shaldon S, Koch KM: Induction of interleukin-1 and interleukin-1 receptor antagonist during contaminated in-vitro dialysis with whole blood. Nephrol Dial Transplant 1996;11:101–108.
17.
Pereira BJG, Snodgrass BR, Hogan PJ, King AJ: Diffusive and convective transfer of cytokine-inducing bacterial products across hemodialysis membranes. Kidney Int 1995;47:603–610.
18.
Hakim RM: Clinical implications of hemodialysis membrane biocompatibility. Kidney Int 1993;44:484–494.
19.
Grooteman MPC, Nubé MJ, Bos JC, van Limbeek J, Schoorl M, van Houte AJ: Ex vivo elution of hemodialyzers: An additional criterion for the assessment of bioincompatibility. Blood Purif 1996;14:321–340.
20.
Grooteman MPC, Nubé MJ, van Houte AJ, Schoorl M, van Limbeek J: Granulocyte sequestration in dialyzers: A comparitive elution study of three different membranes. Nephrol Dial Transplant 1995;10:1859–1864.
21.
Grooteman MPC, Nubé MJ, van Limbeek J, Schoorl M, van Houte AJ: Lymphocyte subsets in dialyzer eluates: A new parameter of bioincompatibility? Nephrol Dial Transplant 1996;11:1073–1078.
22.
Schouten WEM, Nubé MJ, Grooteman MPC, Daha MR, Schoorl M, van Houte AJ: Gene expression of IL-1β in dialyzer eluates. Neth J Med 1996;48:A69.
23.
Tielemans CJ, Delville JPC, Husson CP, Madhoun P, Lambrechts AM, Goldman M, Vanherweghem JL: Adhesion molecules and leukocyte common antigen on monocytes and granulocytes during hemodialysis. Clin Nephrol 1993;39:158–165.
24.
Thylen P, Lundahl J, Fernvik E, Hed J, Svenson SB, Jacobson SH: Mobilization of an intracellular glycoprotein (Mac-1) on monocytes and granulocytes during hemodialysis. Am J Nephrol 1992;12:393–400.
25.
Kaupke CH, Zhang J, Cesario T, Yousefi S, Akeel N, Vaziri ND: Effect of hemodialysis on leukocyte adhesion receptor expression. Am J Kidney Dis 1996;27:244–252.
26.
Tetta C, Tropea F, Camussi G, Neri R, Wratten ML, Sereni L, Silvestro L, Franceschi C, Haeffner-Cavaillon N: Adherence of human monocytes to haemodialysis membranes: LFA 1 (CD11a/CD18), CR1 (CD35) and CR3 (CD11b/CD18) triggering promotes the biosynthesis of platelet-activating factor and adherence. Nephrol Dial Transplant 1995;10:1679–1688.
27.
Ayala A, Ertel W, Chaudry IH: Trauma-induced suppression of antigen presentation and expression of major histocompatibility class II antigen complex in leukocytes. Shock 1996;5:79–90.
28.
Muller Kobold AC, Tulleken JE, Zijlstra JG, Sluiter W, Hermans J, Kallenberg CG, Cohen Tervaert JW: Leukocyte activation in sepsis: Correlation with disease state and mortality. Intensive Care Med 2000;26:883–892.
29.
Van Bokhorst-van der Schuer MA, von Blomberg-van der Flier BM, Riezebos RK, Scholten PE, Quak JJ, Snow GB, van Leeuwen PA: Differences in immune status between well-nourished and malnourished head and neck cancer patients. Clin Nutr 1998;17:107–111.
30.
Nockher WA, Scherberich JE: Monocyte cell-surface CD14 expression and soluble CD14 antigen in hemodialysis: Evidence for chronic exposure to LPS. Kidney Int 1995;48:1469–1476.
31.
Dhondt AW, Vanholder RC, Waterloos MAF, Glorieux GL, Ringoir SMG: Leukocyte CD14 and CD45 expression during hemodialysis: Polysulfone versus cuprophane. Nephron 1996;74:342–348.
32.
Marchant A, Tielemans C, Husson C, Gastaldello K, Schurmans T, De Groote D, Duchow J, Vanherweghem L, Goldman M: Cuprophane haemodialysis induces upregulation of LPS receptor (CD14) on monocytes: Role of complement activation. Nephrol Dial Transplant 1996;11:657–662.
33.
Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC: CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990;249:1431–1433.
34.
Gallay P, Jongeneel CV, Barras C, Burnier M, Baumgartner JD, Glauser MP, Heumann D: Short time exposure to lipopolysaccharide is sufficient to activate human monocytes. J Immunol 1993;150:5086–5093.
35.
Tielemans C, Husson C, Schurmans T, Gastaldello K, Madhoun P, Delville JP, Marchant A, Goldman M, Vanherweghem JL: Effects of ultrapure and non-sterile dialysate on the inflammatory response during in vitro hemodialysis. Kidney Int 1996;49:236–243.
36.
Schouten WEM, Grooteman MPC, van Houte AJ, Schoorl M, van Limbeek J, Nubé MJ: Effects of dialyser and dialysate on the acute phase reaction in clinical bicarbonate dialysis. Nephrol Dial Transplant 2000;15:379–384.
37.
Al-Saady NM, Leatham EW, Gupta S, Kwan JTC, Eastwood JB, Seymour CA: Monocyte expression of tissue factor and adhesion molecules: The link with accelerated coronary artery disease in patients with chronic renal failure. Heart 1999;81:134–140.
38.
Thylen P, Lundahl J, Fernvik E, Brönneberg R, Halldén G, Jacobson SH: Impaired monocyte CD11b expression in interstitial inflammation in hemodialysis patients. Kidney Int 2000;57:2099–2106.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.